1.5-Year Posttreatment Follow-Up of Radium-223 Dichloride (Ra-223) Safety in Patients (Pts) with Castration-Resistant Prostate Cancer (Crpc) and Symptomatic Bone Metastases from Alsympca: Characterization of Hematologic Safety Profiles
Keyword(s):
2015 ◽
Vol 51
◽
pp. S477
◽
Keyword(s):
Keyword(s):
2019 ◽
Vol 24
(5)
◽
pp. 557-566
◽